By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genomic test development firm Med BioGene today reported a loss of C$159,164 ($163,877), or C$.00 on a per-share basis, for the first quarter with no revenues.

The Vancouver, British Columbia-based company also had no revenues for the first quarter of 2010, when it posted a loss of C$453,874, or $.01 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.